Tema Neuroscience and Mental Health ETFMNTL
MNTL
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
33% more funds holding
Funds holding: 3 [Q3] → 4 (+1) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
2.4% less ownership
Funds ownership: 8.23% [Q3] → 5.83% (-2.4%) [Q4]
34% less capital invested
Capital invested by funds: $956K [Q3] → $628K (-$328K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for MNTL.
Financial journalist opinion
Neutral
ETF Trends
3 months ago
Hone Your Biotech Allocation in Neuroscience ETF MNTL
Tech investing poses one of the more important, and more fascinating, questions before investors entering 2025. Tech firms contributed outsized returns for the whole market, but do they pose concentration risks?
Positive
Schwab Network
1 year ago
MNTL ETF: Neuroscience & Mental Health ETF
Tema ETFs recently launched the neuroscience and mental health ETF. MNTL ETF is designed to invest in companies at the forefront of combating neurological diseases and psychiatric disorders.
Neutral
ETF Trends
1 year ago
This Week in ETFs: Closures Outnumber New ETFs
Although 14 new ETFs debuted in the U.S. this past week, closure announcements came in even stronger, largely due to Global X pruning its lineup. Launches during the week included funds from BondBloxx, WisdomTree, Innovator, JPMorgan, and Range ETFs.
Charts implemented using Lightweight Charts™